Corporate venture arm of a large company has set up their fund with $100M to invest each year, with a portion of that going to investments in the life sciences. Within the life sciences, the firm is looking for investments that are both financial and strategic, and will only consider companies that can make use of the parent company’s expertise, or those that align with new strategic areas of interest. The firm is interested in companies with technologies in diagnostic, imaging, omics tools and pharmaceutical manufacturing processes. The firm invests globally, and will consider companies from prototype stage and on. The firm mostly invests in companies at Series B and later, but will consider Series A opportunities as well, and will invest between $0.5-7M per round.

The firm is interested in technologies that can make use of the parent company’s expertise in semiconductors, display, and material engineering. Examples of potential areas of interest include imaging technologies that adapt the company’s inspection ability to detect defects on a nano scale, diagnostics platforms making use of semiconductors or other novel materials as part of their instrumentation and devices, or companies that can adapt the parent company’s advanced manufacturing to control chemical deposition and use different time release formulations to advance drug delivery techniques.

The firm can lead or co-invest, but will take a board observer seat when co-investing, and a board seat when acting as a lead. The firm looks to invest in companies where the expertise of the parent company is applicable to moving the technology forward.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A specialized US venture capital firm under a large China-headquartered company conducts business with a sister company as one group.  The firm has an additional virtual office in USA. The firm is actively seeking investment opportunities from early stage to pre-IPO rounds.  The average size of investment is ~ $5M.  The firm has invested in 17 US & Canada companies since 2016.  The firm can act as the lead investor or co-investor depends on different cases, and the firm prefers to have a board seat.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, and Diagnostics. The firm will also consider orphan drugs and digital health companies.  The firm is open to all kinds of sectors. The firm is open to medical devices with all FDA regulatory pathways, including 510k and PMA.  The firm is open to any phases in medical devices and therapeutics. However, the firm will invest in private companies only.

The firm has no specific requests on the management team.  The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A VC firm headquartered in US has over USD 2.8 billion in assets under management, the firm will consider participating in financing companies throughout all stages but tends to prefer those that are early stage. The firm currently manages a variety of funds and invests in early-stage startups out of a dedicated fund with typical allocations between $150-500k. The firm utilizes various capital structures as determined on a case- by-case basis and has experience with equity investments, debt, convertible loans, and SAFEs. The firm focuses on investment quality over quantity and likes to emphasize being a globally connected firm that will invest regardless of geography.

The firm focuses on markets and founders that are developing technologies with long-term value and growth potential. In the life sciences, the firm is completely sector agnostics and will invest across all modalities within biotechnology, medical technology, digital health, and diagnostics. The firm tends to have a higher bar for biotech and pharma investments compared to the other life science modalities. The firm is phase agnostic and will invest in pre-clinical to on the market therapeutics as well as in development to on the market devices. The firm will invest in all classes of medical devices including Class II (510k) and Class III (PMA). The firm is disease agnostic and will consider companies across all indications.

The firm will work with both experienced and inexperienced management teams that are made up of smart and driven people that are passionate and knowledgeable about their company and technology. The firm will take a board seat as determined on a case-by-case basis and will participate as both a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm invests in breakthrough technologies changing healthcare. The firm invests from pre-see/seed/pre-A. The fund’s LP’s include groups in the healthcare sector. The firm invests in USA, Europe, and Asia.

The firm invests in early stage life science startups with a focus on breakthrough technologies and sciences in healthcare. This includes genomic and synthetic biology technologies, digital health, ML/AI, therapeutics and diagnostics. The firm focuses on pre-IND assets in therapeutics. For technologies regulated as medical devices, the firm focuses on smart medical devices in the pre-commercial stage.

The firm’s partners have a strong clinical perspective; the firm has the capability to help portfolio companies develop clinical resources, and has helped academic scientists form companies to commercialize their discoveries.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.